Table 3.
Colonization with specific organisms that would prevent referral for lung transplant evaluation, grouped by Program type
| All Respondentsa
N = 114 |
Adult Programs N = 57 |
Affiliate Programs N = 12 |
Pediatric Programs N = 43 |
|
|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |
| Burkholderia cenocepacia | 63 (55%) | 37 (65%) | 7 (58%) | 17 (40%) |
| Mycobacterium abscessus | 25 (22%) | 10 (18%) | 4 (33%) | 11 (26%) |
| Burkholderia cepacia complex | 24 (21%) | 15 (26%) | 2 (17%) | 7 (16%) |
| Mycobacterium avium complex (MAC) | 6 (5%) | 3 (5%) | 0 | 3 (7%) |
| Multidrug resistant bacteriab | 3 (3%) | 1 (2%) | 0 | 2 (5%) |
| Aspergillus fumigatus | 1 (1%) | 1 (2%) | 0 | 0 |
| Skipped questionc | 36 (32%) | 16 (28%) | 3 (25%) | 17 (40%) |
aTwo respondents did not report Program type
bMultidrug resistant bacteria, including: Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans
cAssumption: none of these would prevent referral for lung transplant evaluation